Research programme: eye disorder therapies - ExonHit Therapeutics
Alternative Names: EHT 0203; EHT 0204; EHT 203; EHT 204Latest Information Update: 04 Jul 2013
At a glance
- Originator ExonHit Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
- 21 Aug 2009 Discontinued - Preclinical for Eye disorders in France (PO)
- 18 Mar 2008 This programme is still in active development for Eye disorders